

TOCIBRAS – Veiga,VC ; et al. *BMJ* 2021 (Published: Jan 20, 2021)

Study Design	Multicenter, open-label, parallel group, superiority, RCT – Severe/Critical COVID-19 – (1:1)	
Location	Brazil – 9 hospitals	
Inclusion	Severe/Critical COVID-19 pneumonia + Need of O ₂ to keep SpO ₂ >93% or MV <24h + at least 2 elevated biomarkers #(CRP >5mg/dL; Ferritin > 300µg/L; D-dimer > 1000 ng/mL; LDH >ULN)	
Exclusion	AST or ALT increased 5 x ULN, Glomerular filtration rate <30 mL/min/1.72m ²	
Intervention	Tocilizumab 8 mg/kg IV (up to 800 mg)	
Control	Standard of care	
	Tocilizumab n=65	Control n=64
Primary Outcomes		
Clinical status at day 15 on 7-level ordinal scale [#]	12%	19%
Death/MV at day 15	28%	20%
In-hospital mortality	21%***	9%
Death at day 15	17%***	3%
Death at day 28	21%***	9%
Comments:	Trial ended prematurely after first interim analysis due to the number of deaths at 15 days in the tocilizumab group. *** p<0.05 compared to control group # 7-level ordinal scale (1, discharged/ready for discharge; 7, death) Corticosteroids within 7 days prior to first dose was 84% in the toci arm and 89% in the control arm.	
Abbreviations:	AST, aspartate aminotransferase; ALT, alanine aminotransferase; CRP, C-reactive protein; LDH, lactate dehydrogenase; MV, mechanical ventilation; O ₂ , oxygen; RCT, randomized controlled trial; ULN, upper limit of normal.	